Osteoarthritis (“OA”) is the most common chronic degenerative joint disease, characterized by progressive wear of joint cartilage that affects an estimated 51.9 million U.S. adults and 527.8 million adults globally or 15% of adults globally. OA may affect the knees, hips, hands, spine, and other joints with estimated 24.7 million people, 1 in 10 U.S. adults, with knee osteoarthritis. While often considered a disease of old age, an estimated 11.6 million U.S. adults suffering with OA are of working age (20-64 years). The number of knee replacement surgeries is growing every year and expected to rise from approximately 680,000 Americans in 2014 to 1.28 million Americans in 2030.
People living with osteoarthritis may experience a variety of symptoms; for some, pain is mild and occurs occasionally, while for others pain is severe and chronic. Regardless of where patients are in their OA progression, their lives are impacted when everyday activities like walking a few blocks or going up and down stairs cause too much pain. OA is among the most challenging joint diseases to treat, and currently no cure exists. The focus of current OA treatments is to reduce pain and improve function of the affected joints.
The cost burden to the US healthcare system is high, representing hundreds of billions annually with over 900,000 hospitalizations with Joint pain is the primary reason for doctor’s office visits in the US. The Global Knee Osteoarthritis Market size was valued at $ 5.9 Billion in 2022 and is projected to reach $ 13.14 Billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031 according to a new report by Intellectual Market Insights Research.
Macrophages play a critical role in OA pathogenesis through the induction of inflammatory mediators, growth factors and proteinases. AllocetraTM has been developed to reprogram macrophage-associated inflammatory pathways back into their homeostatic states, thereby the use of AllocetraTM in may lead to OA disease amelioration or resolution.